← DBV Technologies S.A. (DBVT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
DBV Technologies S.A. (DBVT)
Biological Products, (No Diagnostic Substances) · market cap $783M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
DBV Technologies S.A. (DBVT) is a French biopharmaceutical company developing its proprietary Viaskin epicutaneous immunotherapy (EPIT) platform, with the lead asset Viaskin Peanut 250 mcg in Phase 3 clinical development for peanut allergy. The company carries a ~$4.9B market cap, $229M in cash representing approximately 14 months of runway, and has been burning roughly $100–120M annually on R&D with minimal revenue. The nearest listed catalyst is an August 4, 2026 earnings report.
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DBV712 250 mcg | Phase 3 | Peanut Allergy |
| Viaskin Milk 150 mcg | Phase 2 | Food Allergy |
| Part A Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy |
| Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy |
| Viaskin Peanut 250mcg | Phase 3 | Peanut Allergy |
| Viaskin Peanut 50 mcg | Phase 2 | Peanut Allergy |
Price & technical context
3-month
-29.1%
6-month
-45.3%
12-month
+12.1%
52-wk range
$10.07–$24.54
vs 50-day MA
-15.8%
vs 200-day MA
-37.4%
Realized vol
73.0%
Max drawdown
-88.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DBVT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.